Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Jury clears J&J of liability in California talc cancer case

A California jury cleared J&J of liability in a case involving a woman who alleged that the company’s talc-based products – including its baby powder – contain asbestos and caused her cancer.

Read More »

Ribometrix Launches With $30 Million to Develop RNA Structure-Based Drugs

Durham, North Carolina-based Ribometrix closed on a Series A financing worth $30 million, led by M Ventures.

Read More »

Sobi buys rights to AstraZeneca infant drug

AstraZeneca took another step to refocus on priority drugs by selling U.S. rights to Synagis for infant lung infections to Swedish Orphan Biovitrum for an upfront fee of $1.5 billion.

Read More »

Nestle raises stake in food allergy drug developer

Nestle’s health science arm will pay $98 million to raise its stake in Aimmune Therapeutics in preparation of submitting a marketing application for the peanut allergy drug AR101 by year-end 2018.

Read More »

AstraZeneca Q3 2018 drug sales turn corner

Strong demand for AstraZeneca’s new drugs – especially those for cancer – drove a return to sales growth in third-quarter 2018 and the drugmaker anticipates years of sustained improvement and rising profit margins.

Read More »

Health stocks up on U.S. vote, insurers hit records

Healthcare stocks rallied with U.S. health insurers reaching record highs as results of the 2018 mid-term elections were seen reducing the likelihood of action to cut medical costs and programs in the world’s biggest and most profitable market.

Read More »

AstraZeneca Sells Asthma and Rhinitis Drugs to Covis

As AstraZeneca focuses on a strategy of divesting assets and spending on the product pipeline, the biopharmaceutical company sold rights to three older drugs to Covis Pharma for $350 million.

Read More »

Illumina to buy rival Pacific Biosciences

Gene sequencing company Illumina Inc. plans to buy Pacific Biosciences of California Inc. in an all-cash deal valued at $1.2 billion.

Read More »

Sanofi and Denali Reach Potential $1+ Billion Deal

Denali announced a collaborative deal with Sanofi to develop potential treatments for neurological and systemic inflammatory diseases that could be worth more than $1 billion.

Read More »

Akoya Biosciences Acquires Phenoptics Portfolio from PerkinElmer

Akoya Biosciences Inc., a Telegraph Hill Partners company, acquired PerkinElmer Inc.’s Phenoptics portfolio.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2018 Focus: Top 50 Pharma, Company of the Year and more!


Ad Right Bottom